GlassScriptPhysician profile
Riichi Andre Ota
NPI 1891318127
$52,689.83
in general payments reported to CMS, 2019-2025
10 companies · $50K in 2025
The $50K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $444 · 2023: $747 · 2024: $1,499 · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $50K · Food and Beverage: $1,330 · Travel and Lodging: $916.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $50,000.00 |
| Food and Beverage | $1,330.39 |
| Travel and Lodging | $915.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $50,000.00 | 2025 | Apollotm |
| Stryker Corporation | $1,116.87 | 2024 | Spinejack |
| Teva Pharmaceuticals USA, INC. | $537.59 | 2022-2024 | Austedo Xr |
| Emd Serono, INC. | $340.70 | 2022-2024 | Mavenclad |
| Ucb, INC. | $152.03 | 2023-2024 | Briviact, Fintepla |
| Genzyme Corporation | $123.25 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $122.79 | 2024 | Zeposia |
| Eisai INC. | $110.69 | 2023 | |
| Argenx US, INC. | $96.13 | 2023 | Vyvgart |
| Tg Therapeutics, INC. | $89.78 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riichi Ota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.